Related Experiment Videos
Infection with Fasciola hepatica
D Y Aksoy1, U Kerimoglu, A Oto
1Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey. duyguyaks@yahoo.com
Summary
Fascioliasis, a liver fluke infection caused by Fasciola hepatica, affects humans worldwide. Diagnosis involves stool tests and imaging, with triclabendazole as the primary treatment.
Area of Science:
- Veterinary Parasitology
- Hepatology
- Infectious Diseases
Background:
- Fascioliasis is a neglected tropical disease caused by Fasciola hepatica, a liver fluke, with humans as accidental hosts.
- The infection presents with distinct hepatic and biliary stages, each exhibiting unique clinical manifestations.
- Global prevalence underscores the importance of understanding its transmission and impact.
Discussion:
- Initial diagnosis relies on non-invasive methods like stool examination and Enzyme-Linked Immunosorbent Assay (ELISA).
- Advanced imaging techniques including CT, ultrasonography, and MRI are crucial for disease confirmation and monitoring progression.
- Invasive procedures such as cholangiography and liver biopsy can supplement diagnosis but are not always necessary.
Key Insights:
- Fascioliasis diagnosis requires a multi-faceted approach, combining serological and imaging modalities.
- Triclabendazole is the established first-line treatment, demonstrating high efficacy against Fasciola hepatica.
- Bithionol serves as a viable alternative therapeutic option when triclabendazole is not suitable.
Outlook:
- Further research into novel diagnostic markers and therapeutic strategies is warranted.
- Public health initiatives focusing on prevention and control in endemic areas are essential.
- Understanding host-parasite interactions can inform future interventions against fascioliasis.